The optimum in minimally invasive, canal-based glaucoma surgery

With a mild touch and manifest efficacy, ABiC™ performed with the iTrack™ surgical system is a comprehensive minimally invasive glaucoma surgery that can effectively reduce IOP and eliminate or reduce the medication burden. Restorative and atraumatic, ABiC™ can be performed across the entire glaucoma disease process – and in conjunction with other treatments and MIGS options.

Related products

Related conditions

Related treatments

Main Image Landing Abic Itrack

No tissue damage, no stents or shunts 

Performed with the iTrack™ surgical system from Ellex, ABiC™ comprehensively addresses blockages in the collector channels and flushes the outflow channels without damaging tissue and without leaving behind a stent or shunt. 

  • Restores the natural outflow pathway —safely and efficaciously
  • Addresses all outflow pathway resistance points — atraumatically
  • Comprehensively addresses blockages in the collector channel ostia
  • Can be performed in conjunction with cataract surgery, and as a standalone procedure
  • Can be performed across the entire glaucoma disease process — before, and after, other MIGS
  • Delivers 30% reduction in mean IOP and a 50% reduction in medication dependence1

Access, catheterize and viscodilate

ABiC™ re-establishes the eye’s natural outflow system by accessing, catheterizing and viscodilating the trabecular meshwork, Schlemm’s canal, and the distal outflow system. 360º viscodilation of Schlemm’s canal can separate the compressed tissue planes of the trabecular meshwork, causing any herniated inner wall tissue to withdraw from the collector channels. This complements the mechanic opening achieved via the circumnavigation of the iTrack™ microcatheter through Schlemm’s canal.

Removing the guesswork from MIGS

The most defining aspect of ABiC™ is its comprehensive approach. To date, ABiC™ is the only minimally invasive glaucoma surgery that successfully and comprehensively addresses all aspects of potential outflow resistance. This contrasts with other MIGS procedures, where only a segment of Schlemm’s canal is addressed, or where the trabecular meshwork is targeted in isolation. When using a stent-based MIGS there is a risk that the area of blockage will be missed or sub optimally treated.

Reduce medication dependence safely and effectively

ABiC™ performed with the iTrack™ surgical system is both safe and effective. On average, it achieves a reduction in IOP of 30% and a 50% reduction in medication dependence.1

Standalone or complementary

Intuitive and efficient, ABiC™ can be performed as a standalone procedure, or in conjunction with cataract surgery.

ABiC™ can also be deployed synergistically with Selective Light Therapy (SLT) to control IOP by restoring the natural outflow pathways. SLT stimulates cellular regeneration to create a healthier, more porous trabecular meshwork structure, and achieves an average 30% reduction in IOP when used as a first-line therapy. Additionally, ABiC™ can be used in conjunction with other MIGS devices or treatments — and, as an atraumatic procedure, it does not preclude future treatment options.

1. 228-eye ABiC 12-Month Case Series Data, presented at ASCRS 2016. Data on file. Ellex Medical.

“I have been a practicing glaucoma specialist for over 10 years. The introduction of ABiC has completely changed my glaucoma treatment paradigm. Not only has ABiC proven itself to be highly effective in lowering IOP and reducing medication dependence, it also offers an excellent safety profile. There is no manipulation of the conjunctiva, and the post-op recovery resembles that of cataract surgery.”

ABiC™ resources


Meet the Masters of the New Comprehensive MIGS

This article discusses the role of ABiC, which has grown into a procedure that is effective, safe and easily combined with other MIGS interventions. Contributing authors include Mahmoud Khaimi, MD (USA), Norbert Koerber, MD, PhD (Germany), Mark Gallardo, MD (USA), Sev Teymoorian, MD (USA) and Leon Au, MD (UK).

Case Study

MIGS: Restoration of Normal Outflow Aqueous Pathways

The March 2018 issue of CRST featured a case study by Dr. David Lubeck in which ABiC was successfully performed in a patient post-SLT and iStent – speaking to the versatility of iTrack in clinical practice.

Case Study

MIGS: A New Paradigm to Treat Glaucoma

Featuring Dr. Mahmoud Khaimi, this CRST article features a case study on the synergies of ABiC and SLT – and the benefits of performing these two procedures in combination.


ABiC Whitepaper: The Minimally Invasive Glaucoma Surgery that Keeps its Promise

This whitepaper presents the preliminary 12-month results for ABiC, based on a 228-eye case series by Mahmoud A. Khaimi, MD and Mark J. Gallardo, MD.


Roundtable Discussion, MIGS with ABiC

Featuring Ike K. Ahmed, MD, this panel discussion on microinvasive glaucoma surgery (MIGS) addresses the collective wisdom and experiences of a leading panel of MIGS experts.


ABiC In the Media, Glaucoma Today

In this article ABiC pioneer Mahmoud A. Khaimi, MD addresses his experience with ABiC, contrasting it against the other MIGS procedures available.

Associated websites

Physician iTrack Blog

Read about the role of MIGS, including iTrack, in the glaucoma treatment algorithm. Blog curated by Mark J. Gallardo, MD (USA).

Associated websites

iTrack Patient Education

A simple three-step procedure, learn how ABiC™ can reduce the elevated intraocular pressure associated with glaucoma.


ABiC: A Comprehensive Solution

In this video interview, glaucoma expert Mahmoud A. Khaimi, MD (USA), describes the advent of ABiC™ performed with the iTrack™ surgical system.


ASCRS Glaucoma Roundtable: ABiC in the Spotlight

Iqbal Ike K. Ahmed, MD, FRCSC, asks a group of experts to address the misconceptions and barriers to adoption for ab interno canaloplasty (ABiC).


ASCRS Glaucoma Roundtable: MIGS in Daily Practice

Iqbal Ike K. Ahmed, MD, FRCSC, opens up discussion on preferred minimally invasive glaucoma surgery (MIGS) procedures.


ABiC: iTrack Animation

Watch the iTrack™ as it circumnavigates Schlemm’s, separating the herniations of the meshwork into the collector channels and breaking inner lumen adhesions.


ABiC: Restoring the Outflow Pathway

In this video Mahmoud A. Khaimi, MD (USA) demonstrates restoration of the natural outflow pathway with ABiC™.


ABiC According to the Expert

According to iTrack™ expert Mark J. Gallardo, MD (USA), proper visualization of the nasal drainage angle is crucial to the success of ABiC™.

Contact us

Ellex is the manufacturer of the iTrack Canaloplasty microcatheter for the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma. It has been approved for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm’s canal during the ABiC (ab-interno Canaloplasty) procedure. Ellex does not accept any responsibility for use of the iTrack Canaloplasty microcatheter outside of these indications.

iTrack™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) # K080067 for the treatment of open-angle glaucoma.

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More